2021년12월02일thu
로그인 | 회원가입
OFF
트위터로 보내기 싸이월드 공감
기사글확대 기사글축소 기사스크랩 이메일문의 프린트하기
OS in Relapsed/Refractory B-cell acute Lymphoblastic leukemia patients receiving Inotuzumab-ozogamicin VS Standard care in Phase3 Study
Hagop M Kantarjian, Daniel J DeAngelo, Anjali S Advani, Michaela Liedtke, Wendy Stock, Nicola Goekbuget, Susan O'Brien, Giovanni Martinelli, Kongming Wang, Tao Wang, M Luisa Paccagnella, Barbara Sleight, Erik Vandendries, Matthias Stelljes
[ 2016년 06월 14일 10시 54분 ]

Background


CD22 is expressed in most (>90%) cases of B-cell acute lymphoblastic leukemia (ALL) and is an attractive target for the treatment of B-cell malignancies. Inotuzumab ozogamicin (InO), a humanized anti-CD22 antibody conjugated to calicheamicin, has demonstrated significantly superior response vs standard care (SC) in the first 218 randomized patients with relapsed/refractory (R/R) ALL in the phase 3 INO-VATE trial.


Aims


To assess overall survival (OS) and progression free survival (PFS) of adults with R/R ALL receiving InO vs SC.


Methods


In this ongoing global, 2-arm, randomized phase 3 trial (NCT01564784), patients with R/R ALL (including ~15% of patients in each arm with Philadelphia-positive ALL) due to receive salvage (S) 1 or 2 therapy were randomized to InO (starting dose 1.8 mg/m2/cycle [0.8 mg/m2 on day 1; 0.5 mg/m2 on days 8 and 15 of a 21–28 day cycle (≤6 cycles)]) or SC (either fludarabine/cytarabine [ara-C]/granulocyte colony-stimulating factor [FLAG], ara-C plus mitoxantrone, or high-dose ara-C). Study was designed with two primary endpoints: 1) OS and 2) complete remission (CR)/CR with incomplete hematologic recovery (CRi) assessed in first 218 patients randomized (results previously presented). Overall study-wise type-I error was controlled by splitting 1-sided α to 0.0125 for each endpoint. Safety was assessed in all patients who received ≥1 dose of study drug. Per protocol, the final OS analysis was to occur upon observing ~248 events; 252 events (122 with InO and 130 with SC) were observed on March 8, 2016; data as of this date are presented.


Results


The ITT analysis population included 326 patients with both arms being well balanced for baseline stratification factors. The OS hazard ratio (HR) between InO and SC was 0.77 (97.5% CI, 0.58‒1.03) with 1-sided P=0.0203 and median OS 7.7 [95% CI, 6.0‒9.2] vs 6.7 [95% CI, 4.9‒8.3] months. The second primary objective of demonstrating a statistically significant improvement in final OS with InO vs SC was not met at prespecified significance level of 0.0104. The 2-year OS rate for InO vs SC was 23% (95% CI, 16‒30%) vs 10% (95% CI, 5‒16%). It was noted, however, that the OS departed from the proportional hazards assumption. Given this, a restricted mean survival time (RMST) analysis was applied and showed: mean OS was 13.9 months for InO vs 9.9 months for SC, a difference that met statistical significance. PFS was significantly longer with InO vs SC (HR, 0.45 [97.5% CI, 0.34‒0.61]; 1-sided P<0.0001), with median PFS 5.0 [95% CI, 3.7‒5.6] vs 1.8 [95% CI, 1.5‒2.2] months. Follow-up of previously reported endpoints, including objective response, MRD-negativity, and SCT rates were all superior in the InO arm compared to the SC arm by protocol-specified criteria. Updated safety results demonstrate a tolerability and toxicity profile consistent with that reported previously.


Conclusion

Compared with SC, InO provided evidence of longer OS and significantly prolonged PFS in adult patients with R/R ALL.

데일리메디 dailymedi@dailymedi.com
이기자의 다른뉴스보기
무통장입금 정보입력 입금자명 입금예정일자
(입금하실 입금자명 + 입금예정일자를 입력하세요)
[관련뉴스]
- 관련뉴스가 없습니다.
트위터로 보내기 싸이월드 공감
기사글확대 기사글축소 기사스크랩 이메일문의 프린트하기
삼성서울병원 기획실장 김희철‧외과장 김지수‧건강의학센터장 홍진표‧진료운영실장 임도훈‧외래부장 온영근 外
GC 김연근 경영관리실장·김중수 경영지원실장-GC녹십자 김성화 오창공장장 外
이민정·조범주 교수(한림대성심병원 안과), 대한안과학회 학술상
정형외과의사회, 올해 인물상 김강립 식약처장
삼성서울병원 커뮤니케이션실장 이상철 교수·차장 유종한 교수
김태식 한국유나이티드제약 전무, 탈북 청소년 美대학 장학금 수여
대한당뇨병학회 신임 회장 백세현(고대구로병원)
임태강 교수·이종헌 전공의(노원을지대병원 정형외과), 대한정형외과 초음파학회 최우수 학술상
신현영 의원, 더불어민주당 2021년 국정감사 우수의원
대한비뇨의학과의사회, 의협회관 신축기금 2000만원
최영화 아주대병원 감염내과 교수, 대한에이즈학회장 취임
대한비뇨의학회, 의협회관 신축 기금 3000만원
이권용 메디파인 대표이사 별세
김승일 산부인과 전문의 장모상